Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara K Burton

Showing results (11-20 of 122) with videos related to

Pageof 13
Sort By:
Pediatrics|February 6, 2008
Successful management of difficult infusion-associated reactions in a young patient with mucopolysaccharidosis type VI receiving recombinant human arylsulfatase B (galsulfase [Naglazyme])Katherine H Kim, Celeste Decker, Barbara K Burton
Molecular Genetics and Metabolism Reports|June 27, 2017
Successful reduction of high-sustained anti-idursulfase antibody titers by immune modulation therapy in a patient with severe mucopolysaccharidosis type IIKatherine H Kim, Yoav H Messinger, Barbara K Burton
Molecular Genetics and Metabolism|July 13, 2013
High dose genistein aglycone therapy is safe in patients with mucopolysaccharidoses involving the central nervous systemKatherine H Kim, Charlotte Dodsworth, Andrea Paras, et al.
Journal of Inherited Metabolic Disease|September 10, 2017
Survival in idursulfase-treated and untreated patients with mucopolysaccharidosis type II: data from the Hunter Outcome Survey (HOS)Barbara K Burton, Virginie Jego, Jaromir Mikl, et al.
Molecular Genetics and Metabolism|May 12, 2009
Home infusion therapy is safe and enhances compliance in patients with mucopolysaccharidosesBarbara K Burton, Chani Wiesman, Andrea Paras, et al.
Molecular Genetics and Metabolism|July 20, 2010
Sapropterin therapy increases stability of blood phenylalanine levels in patients with BH4-responsive phenylketonuria (PKU)Barbara K Burton, Heather Bausell, Rachel Katz, et al.
Molecular Genetics and Metabolism|November 20, 2025
Evaluation and follow-up of newborns screening positive for mucopolysaccharidosis II: Results from an international modified Delphi consensusBarbara K Burton, N Matthew Ellinwood, Katey K Hoffman, et al.
Acta Paediatrica (Oslo, Norway : 1992)|January 23, 2013
Mucopolysaccharidosis type III (Sanfilippo syndrome) and misdiagnosis of idiopathic developmental delay, attention deficit/hyperactivity disorder or autism spectrum disorderFrits A Wijburg, Grzegorz Węgrzyn, Barbara K Burton, et al.
Pediatrics|November 23, 2017
The Initial Evaluation of Patients After Positive Newborn Screening: Recommended Algorithms Leading to a Confirmed Diagnosis of Pompe DiseaseBarbara K Burton, David F Kronn, Wuh-Liang Hwu, et al.
Molecular Genetics and Metabolism Reports|September 1, 2022
Pegvaliase dose escalation to 80 mg daily may lead to efficacy in patients who do not exhibit an optimal response at lower dosesErika R Vucko, Kirsten E Havens, Joshua J Baker, et al.
Pageof 13

Showing results (11-20 of 122) with videos related to

Sort By:
Pageof 13
Pediatrics|February 6, 2008
Successful management of difficult infusion-associated reactions in a young patient with mucopolysaccharidosis type VI receiving recombinant human arylsulfatase B (galsulfase [Naglazyme])Katherine H Kim, Celeste Decker, Barbara K Burton
Molecular Genetics and Metabolism Reports|June 27, 2017
Successful reduction of high-sustained anti-idursulfase antibody titers by immune modulation therapy in a patient with severe mucopolysaccharidosis type IIKatherine H Kim, Yoav H Messinger, Barbara K Burton
Molecular Genetics and Metabolism|July 13, 2013
High dose genistein aglycone therapy is safe in patients with mucopolysaccharidoses involving the central nervous systemKatherine H Kim, Charlotte Dodsworth, Andrea Paras, et al.
Journal of Inherited Metabolic Disease|September 10, 2017
Survival in idursulfase-treated and untreated patients with mucopolysaccharidosis type II: data from the Hunter Outcome Survey (HOS)Barbara K Burton, Virginie Jego, Jaromir Mikl, et al.
Molecular Genetics and Metabolism|May 12, 2009
Home infusion therapy is safe and enhances compliance in patients with mucopolysaccharidosesBarbara K Burton, Chani Wiesman, Andrea Paras, et al.
Molecular Genetics and Metabolism|July 20, 2010
Sapropterin therapy increases stability of blood phenylalanine levels in patients with BH4-responsive phenylketonuria (PKU)Barbara K Burton, Heather Bausell, Rachel Katz, et al.
Molecular Genetics and Metabolism|November 20, 2025
Evaluation and follow-up of newborns screening positive for mucopolysaccharidosis II: Results from an international modified Delphi consensusBarbara K Burton, N Matthew Ellinwood, Katey K Hoffman, et al.
Acta Paediatrica (Oslo, Norway : 1992)|January 23, 2013
Mucopolysaccharidosis type III (Sanfilippo syndrome) and misdiagnosis of idiopathic developmental delay, attention deficit/hyperactivity disorder or autism spectrum disorderFrits A Wijburg, Grzegorz Węgrzyn, Barbara K Burton, et al.
Pediatrics|November 23, 2017
The Initial Evaluation of Patients After Positive Newborn Screening: Recommended Algorithms Leading to a Confirmed Diagnosis of Pompe DiseaseBarbara K Burton, David F Kronn, Wuh-Liang Hwu, et al.
Molecular Genetics and Metabolism Reports|September 1, 2022
Pegvaliase dose escalation to 80 mg daily may lead to efficacy in patients who do not exhibit an optimal response at lower dosesErika R Vucko, Kirsten E Havens, Joshua J Baker, et al.
Pageof 13